{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:01:19Z","timestamp":1777334479314,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>We experienced a case of rheumatoid arthritis and JAK2V617F mutation\u2013positive essential thrombocythemia treated with baricitinib. The patient was a 72-year-old male. He was diagnosed with rheumatoid arthritis at a local clinic in April 2018. Methotrexate (MTX) was started and the dose was increased to 16\u2009mg\/week. In October of the same year, anaemia was observed and MTX was reduced, but anaemia progressed. Blood tests showed pancytopenia, and he was referred to Rheumatology on suspicion of drug-induced pancytopenia. Pancytopenia improved with discontinuation of MTX and administration of folic acid. His platelet count was markedly increased to 1,400,000\/\u03bcl at one point, decreased to 400,000\/\u03bcl, and then gradually increased to 700,000\u20131,000,000\/\u03bcl. Despite taking an antiplatelet drug, he developed cerebral infarction in June 2019. The JAK2V617F mutation was noted, and he was diagnosed with essential thrombocythemia. Hydroxycarbamide was started, but the effect was insufficient. Baricitinib, a JAK1\/2 inhibitor indicated for rheumatoid arthritis, was started in August with the expectation that it would also be effective for essential thrombocythemia. The platelet count decreased to \u223c400,000\u2013600,000\u2009cells\/\u03bcl, and a decrease in the C-reactive protein level and the improvement of arthritis were noted. We report this case because it is considered to be a valuable case, suggesting that baricitinib may be effective for essential thrombocythemia.<\/jats:p>","DOI":"10.1093\/mrcr\/rxad012","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T13:53:42Z","timestamp":1685454822000},"page":"1-4","source":"Crossref","is-referenced-by-count":2,"title":["A case in which baricitinib was effective for both rheumatoid arthritis and essential thrombocythemia"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-1670","authenticated-orcid":false,"given":"Rioko","family":"Migita","sequence":"first","affiliation":[{"name":"Rheumatology, Japanese Red Cross Fukuoka Hospital , Fukuoka, Japan"},{"name":"Internal medicine, Kyushu University Beppu Hospital , Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Rheumatology, Japanese Red Cross Fukuoka Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"Rheumatology, Japanese Red Cross Fukuoka Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Hiura","sequence":"additional","affiliation":[{"name":"Internal medicine, Kyushu University Beppu Hospital , Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Kimoto","sequence":"additional","affiliation":[{"name":"Internal medicine, Kyushu University Beppu Hospital , Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Internal medicine, Kyushu University Beppu Hospital , Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Rheumatology, Japanese Red Cross Fukuoka Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"2023122911390356600_R1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"2023122911390356600_R2","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023122911390356600_R3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/13543784.2014.918604","article-title":"Selective JAK inhibitors in development for rheumatoid arthritis","volume":"23","author":"Norman","year":"2014","journal-title":"Exp Opin Invest Drugs"},{"key":"2023122911390356600_R4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2023122911390356600_R5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11899-015-0278-x","article-title":"Oncogenic drivers in myeloproliferative neoplasms: from JAK2 to calreticulin mutations","volume":"10","author":"Cahu","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"2023122911390356600_R6","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"2023122911390356600_R7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"2023122911390356600_R8","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","article-title":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results","volume":"130","author":"Verstovsek","year":"2017","journal-title":"Blood"},{"key":"2023122911390356600_R9","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"2023122911390356600_R10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Ann Rev Immunol"},{"key":"2023122911390356600_R11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/rheumatology\/keu430","article-title":"The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels","volume":"54","author":"Isomaki","year":"2015","journal-title":"Rheumatology"},{"key":"2023122911390356600_R12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2023122911390356600_R13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2023122911390356600_R14","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.110.033787","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans","volume":"38","author":"Shilling","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2023122911390356600_R15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"2023122911390356600_R16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023122911390356600_R17","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2V617F mice","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res"},{"key":"2023122911390356600_R18","first-page":"684","article-title":"JAK2 V617F-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Transl Sci"},{"key":"2023122911390356600_R19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/cancers12092700","article-title":"Risk of inflammatory bowel disease in patients with chronic myeloproliferative neoplasms: a Danish nationwide cohort study","volume":"12","author":"Bak","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2023122911390356600_R20","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"2023122911390356600_R21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00296-010-1747-0","article-title":"Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia","volume":"32","author":"Ayvaz","year":"2012","journal-title":"Rheumatol Int"},{"key":"2023122911390356600_R22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.12669\/pjms.344.15281","article-title":"An elusive case of digital ischemia in a patient with rheumatoid arthritis","volume":"34","author":"Azam","year":"2018","journal-title":"Pak J Med Sci"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxad012\/50487311\/rxad012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/1\/1\/54920043\/rxad012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/1\/1\/54920043\/rxad012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T12:27:27Z","timestamp":1703852847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/8\/1\/1\/7186275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,18]]},"published-print":{"date-parts":[[2023,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxad012","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,5,18]]}}}